Generic drug manufacturers Zydus Lifescienes have received final approval from the Diltyzem hydrochloride tablets USP, 30 mg, 60 mg, 90 mg, and US Food and Drug Administration (US FDA) for 120 mg.
A normal, the drug is indicated to the management of chronic stable angina and angina due to a normal, a common, drug due to coronary artery cramps. DILTIAZEM Hydrochloride tablets had an annual sales of $ 13.9 million in the US, Zydus said, Iqvia mat June 2025.
The approved drug will be produced at its plant in Baddi, Himachal Pradesh. Calcium-channel, belonging to a square of drugs called clocles, works comfortably, delytiazum blood vessels, which reduces the work on the heart and increase the supply of blood and oxygen to the heart muscles.
Shares of Zydus Lifescienes closed on BSE 2.18% more .18% more.
Published – August 11, 2025 10:47 pm IST
